Catalyst Biosciences, Inc.
611 Gateway Blvd.
South San Francisco
About Catalyst Biosciences, Inc.
We are a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hemostasis and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (“AMD”). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
138 articles with Catalyst Biosciences, Inc.
Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the presentation of a poster, in collaboration with partner Mosaic Biosciences, at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28-May 2, 2019.
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
Catalyst Biosciences, Inc. (NASDAQ: CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) currently being developed for the treatment of hemophilia A or B with inhibitors. The data were delivered in an oral presentation at the 12TH Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held Feb. 6-8, 2019 in Prague.
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
atalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications presented preclinical proof-of-concept data of CB 2679d-GT Factor IX gene therapy in hemophilia B mice.
Catalyst Biosciences, Inc. (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019.
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Hemophilia and Allied Disorders
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced oral and poster presentations at the 12TH Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in Prague from February 6-8, 2019.
All of the shares in the offering are to be sold by the Company.
Additionally, the Company has granted the underwriters an option to purchase up to an additional 441,176 shares of its common stock, at the price to the public.
Catalyst Biosciences Announces Positive Top-Line Data from Phase I/II Study of Subcutaneous CB 2679d/ISU304 in Individuals With Hemophilia B
Results from the trial showed a continuous linear increase in Factor IX activity levels following daily dosing of CB 2679d for six days.
Catalyst Biosciences Initiates Phase II/III Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B With Inhibitors
This Phase 2 open-label, subcutaneous efficacy trial in individuals with hemophilia A or B with inhibitors will evaluate the ability of MarzAA to eliminate, or minimize, spontaneous bleeding episodes.
JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. are acting as Joint Book-running Managers and LifeSci Capital LLC is acting as a Co-Manager for the proposed offering.
Catalyst Biosciences today announced the pricing of an underwritten public offering of 1,105,263 shares of its common stock, offered at a price of $9.50 per share to the public.
The Company anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion and to meet working capital needs.
Catalyst Biosciences Announces Acceleration of Phase I/II Trial of CB 2679d/ISU304 in Individuals with Hemophilia B
Catalyst Biosciences today announces that the Korean MFDS has approved a protocol amendment to omit single dose Cohort 4 and move directly to multi-dose Cohort 5 at 150 IU/kg daily, in the ongoing Phase 1/2 multi-dose study of CB 2679d/ISU304, Catalyst's highly potent next-generation coagulation Factor IX variant in individuals with severe hemophilia B.
Mr. Williams was most recently senior vice president of biopharmaceuticals at Novo Nordisk.
Catalyst Biosciences Announces Interim Phase I/II CB 2679d/ISU304 Results at the American Society of Hematology Conference
The data demonstrate that subcutaneous delivery of CB 2679d significantly increases the factor IX (FIX) activity half-life to 98.7 hours.
Catalyst Biosciences Strengthens Clinical Hemophilia Programs With Additions to its Senior Leadership Team
The company appointed Arwa Shurrab as vice president of regulatory affairs and Jamie Ellen Siegel, M.D., as the head of clinical development.
Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
Cash, cash equivalents and short-term investments, as of Sept. 30, 2017, were $27.5 million.
Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors
Ms. Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology, Ophthalmology at Shire.
Catalyst Biosciences Granted FDA Orphan Drug Designation For Subcutaneous Recombinant Human Factor IX Variant For Treatment Of Hemophilia B
Catalyst Biosciences Announces Successful Completion Of First Subcutaneous Dosing Cohort In Ongoing Hemophilia B Clinical Trial